Xencor Inc — Form 10-Q
Filed November 4, 2026 · analyzed by the Periodic Agent
10-Q
▲ Likely positive
significance 71/100
What the filing says
Xencor and Alexion Pharma International Operations Limited (successor to Alexion Pharmaceuticals) settled a dispute over U.S. royalty payments under their January 2013 license agreement. Alexion will pay Xencor $52.5M on July 29, 2026, and another $52.5M on July 29, 2027 (total $105M). Upon receipt of the first payment, Xencor releases all past claims related to U.S. royalties but retains rights to royalties outside the U.S. and other non-royalty rights under the License Agreement. The settlement includes a 1.5% monthly late fee if payments are not received by the due dates.
Why this rating
Settlement worth 18.9% of current market cap ($105M ÷ $555.9M) is material. Cash inflow is significant but non-recurring; does not change ongoing royalty disputes beyond U.S. sales. Moderate business-changing significance.
Price action (we called it positive)
before filing · preread $35.03 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.